This company listing is no longer active
Albireo Pharma Résultats passés
Passé contrôle des critères 0/6
Informations clés
-18.1%
Taux de croissance des bénéfices
-3.0%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 49.3% |
Rendement des fonds propres | -131.1% |
Marge nette | -228.5% |
Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Ventilation des recettes et des dépenses
Comment Albireo Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Sep 22 | 57 | -131 | 80 | 87 |
30 Jun 22 | 51 | -36 | 77 | 85 |
31 Mar 22 | 45 | -33 | 72 | 83 |
31 Dec 21 | 41 | -34 | 71 | 81 |
30 Sep 21 | 11 | -48 | 65 | 81 |
30 Jun 21 | 9 | -136 | 59 | 82 |
31 Mar 21 | 9 | -120 | 51 | 79 |
31 Dec 20 | 8 | -108 | 44 | 76 |
30 Sep 20 | 12 | -90 | 35 | 70 |
30 Jun 20 | 11 | -82 | 30 | 60 |
31 Mar 20 | 11 | -78 | 27 | 53 |
31 Dec 19 | 10 | -63 | 24 | 45 |
30 Sep 19 | 4 | -71 | 23 | 41 |
30 Jun 19 | 3 | -63 | 21 | 38 |
31 Mar 19 | 2 | -61 | 20 | 34 |
31 Dec 18 | 13 | -46 | 18 | 31 |
30 Sep 18 | 12 | -35 | 17 | 26 |
30 Jun 18 | 12 | -28 | 17 | 19 |
31 Mar 18 | 11 | -19 | 17 | 16 |
31 Dec 17 | 0 | -24 | 16 | 13 |
30 Sep 17 | 3 | -31 | 16 | 10 |
30 Jun 17 | 3 | -28 | 13 | 9 |
31 Mar 17 | 11 | -20 | 12 | 9 |
31 Dec 16 | 11 | -16 | 10 | 8 |
30 Sep 16 | 13 | -5 | 8 | 8 |
30 Jun 16 | 13 | -4 | 8 | 7 |
31 Mar 16 | 5 | -8 | 5 | 6 |
Des revenus de qualité: ALBO is currently unprofitable.
Augmentation de la marge bénéficiaire: ALBO is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accélération de la croissance: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Rendement des fonds propres
ROE élevé: ALBO has a negative Return on Equity (-131.05%), as it is currently unprofitable.